![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 46, 32565-32573, November 12, 1999
From the Departments of Immunology and Cell Biology, The Scripps
Research Institute, La Jolla, California 92037
p21-activated kinases (Pak)/Ste20 kinases are
regulated in vitro and in vivo by the small
GTP-binding proteins Rac and Cdc42 and lipids, such as sphingosine,
which stimulate autophosphorylation and phosphorylation of exogenous
substrates. The mechanism of Pak activation by these agents remains
unclear. We investigated Pak kinase activation in more detail to gain
insight into the interplay between the GTPase/sphingosine binding, an
intramolecular inhibitory interaction, and autophosphorylation. We
present biochemical evidence that an autoinhibitory domain (ID)
contained within amino acid residues 67-150 of Pak1 interacts with the
carboxyl-terminal kinase domain and that this interaction is regulated
in a GTPase-dependent fashion. Cdc42- and
sphingosine-stimulated Pak1 activity can be inhibited in
trans by recombinant ID peptide, indicating similarities in
their mode of activation. However, Pak1, which was autophosphorylated in response to either GTPase or sphingosine, is highly active and is
insensitive to inhibition by the ID peptide. We identified phospho-acceptor site threonine 423 in the kinase activation loop as a
critical determinant for the sensitivity to autoinhibition and
enzymatic activity. Phosphorylation studies suggested that the
stimulatory effect of both GTPase and sphingosine results in exposure
of the activation loop, making it accessible for intermolecular phosphorylation.
Localized regulation of protein kinase activity is an essential
means to ensure spatial and temporal control of signaling events in a
cellular environment. Hormonal or other stimuli are usually necessary
to switch a kinase into a catalytically competent state, allowing
phosphorylation of substrates to take place. An emerging regulatory
theme is that inhibitory mechanisms exist to keep protein kinases in an
inactive state (1, 2), and that relief of such inhibition allows
activation to occur. Kinases often act autocatalytically to
phosphorylate key amino acid residues that relieve autoinhibition and
enhance catalytic efficiency. Alternatively, exogenous kinases may also
serve this role. However, activation must be reversed in the absence of
the stimulus, and dephosphorylation by protein phosphatases is thought
to mediate switching the active kinase back to an inactive or
basally activated state.
p21-activated kinases (Paks)1
belong to a growing family of serine/threonine kinases involved in the
control of various cellular processes, including the cell cycle,
dynamics of the cytoskeleton, apoptosis, and transcription (3). Pak
kinase activity is regulated by members of the Rho family of GTPases,
specifically Cdc42 and Rac. These GTPases bind to Pak kinase solely in
their active forms, i.e. the GTP-bound state, resulting in
stimulation of the kinase activity both in vitro and
in vivo. The molecular details of how the GTPases exert
their effect on the kinase to induce its activation remain unclear,
however. Several lines of evidence suggested that the amino-terminal
non-kinase region of Pak, in which the Cdc42/Rac-binding site is
located, is crucial for the regulation of kinase activity. It has been
shown by several groups that removal of the NH2-terminal portion of Pak by protease digestion leads to activation of the kinase
fragment (4, 5). A physiologically relevant example is known for the
62-kDa isoform Pak2, which has been shown to be cleaved and activated
by the cysteine protease caspase-3 in response to apoptosis-inducing
stimuli (6-8).
Zhao et al. (9) have recently used mutational analysis to
characterize a region in the NH2-terminal regulatory domain
of Pak adjacent to the p21-binding domain that is important for the inhibition of kinase activity. Using a plasmid injection approach, they
showed that cellular effects that depend on Pak kinase activity, including dissolution of actin stress fibers and focal adhesions, can
be blocked by coexpression of the autoinhibitory region. Similar conclusions were reached using a genetic analysis of
Schizosaccharomyces pombe Pak1 (10). We undertook a
biochemical approach to characterize an interaction between the Pak1
kinase domain and the regulatory amino terminus. We localized the
interacting site in the NH2 terminus to the same area as
the autoinhibitory domain (ID) characterized by Zhao et al.
(9). Our data suggest that the interaction observed is responsible for
maintaining the kinase in an inactive state. Cdc42 was able to disrupt
the interaction, but only in the GTP-bound active form. Using
characterized mutations in Pak1 that abolish GTPase binding or
inactivate the inhibitory function, we could show that the p21-binding
and autoinhibitory domains are separable but overlapping. Recently, we
have demonstrated that sphingosine is an activator of human Pak1
in vitro and in vivo (11), although the
activation by the lipid in vivo is controversial (12). We observed that, at non-saturating concentrations, sphingosine-induced Pak1 activation was also sensitive to the autoinhibitory peptide, suggesting that the lipid mediates activation of Pak1 via a similar mechanism, i.e. relief of autoinhibition by the
NH2-terminal ID domain. We demonstrate that one major
phosphorylation event on residue threonine 423 within the COOH-terminal
kinase domain renders the kinase activity independent of the
autoinhibitory module and simultaneously increases its specific
activity. Both Cdc42 and sphingosine act on Pak1 kinase to expose
threonine 423, which in turn becomes accessible for
cross-phosphorylation.
Materials--
Cell culture medium, fetal bovine serum and
supplements were from Life Technologies, Inc.
[ Plasmid DNA and Constructions--
pGEX-KG/rpak1
(233-544) was kindly provided by Melanie H. Cobb (University of Texas
Southwestern Medical Center, Dallas, TX). pCMV6M is a myc
tag-containing derivative of pCMV5 and has been described elsewhere
(13). All Pak1 variants (human Pak1 wild type, Pak1-(T423E),
Pak1-(T423A), Pak1-(H83L,H86L), Pak1-(L107F), Pak1-(K299A) were
inserted into pCMV6M and contain a myc epitope at the amino
terminus for detection. The threonine to alanine exchange at position
423 in hPak1 was introduced using oligonucleotides (5'-CAGAGCAAACGGAGCgCCATGGTAGGAACCCC-3' and the complementary oligonucleotide) and the Quikchange Site-directed mutagenesis kit of
Stratagene, La Jolla.
The NH2-terminal fragments of hpak1 (amino acid 1-234:
hpak1-(1-234), aa 67-150: hpak1-(67-150) and mutated derivative
H83L,H86L) were subcloned in pET28a (Novagen, Madison). The wild type
and H83L,H86L mutation of hpak1-(1-234) were amplified by PCR from the
corresponding pCMV6M/hPak1 derivatives using primers pT637 and
OP1/234-3' (5'-CCG GAA TTC TTA AGC ATC TGG TGG
AGT GGT-3'), cut with BamHI and EcoRI, and
inserted into BamHI-EcoRI-cut pET28a. The
p21-binding domain (PBD)/ID wild type fragment (amino acid 67-150) was
produced by PCR using primers OP1/67-5' (5'-CGC GGA TCC AAG AAA GAG AAA GAG CGG-3') and OP1/150-3' (AAG GAA
AAA AGC GGC CGC GTC GAC TCA AGC TGA CTT ATC TGT
AAA GCT-3'), cut with BamHI and EcoRI, and
inserted into pET28a. The PBD/ID fragments containing the H83L,H86L or
the L107F mutations were amplified from the corresponding full-length
hPak1 cDNA clones and inserted by BamHI and
EcoRI restriction into pET28a. To produce H83L and H86L
single mutations in the PBD/ID fragment, overlapping PCR was performed
using OP1/67-5' and OP1/150-3' as outer boundary primers and
overlapping primer pairs to introduce the desired mutations (for H83L:
forward primer 5'-TCA GAT TTT GAg CtC ACA ATT CAT-3' and reverse primer
5'-ATG AAT TGT GaG cTC AAA ATC TGA-3'; for H86L: forward primer 5'-GAA
CAC ACA Ata Cta GTC GGT TTT-3' and reverse primer 5'-AAA ACC GAC taG
tAT TGT GTG TTC-3'; lowercase letters indicate the introduced base mutations).
The COOH-terminal kinase domains of human Pak1 (amino acids 232-545)
was amplified by PCR (primers for hpak1-(232-545): 5'-GC GGA TCC CCA GAT GCT TTG ACC CGG-3', 5'-G CCG
GTC GAC TTA GTG ATT GTT CTT TG-3'). The hpak1
fragment was cut with BamHI-SalI and inserted
into BamHI-SalI-cut pET28a.
Purification of Recombinant Proteins--
The
GST-rpak1-(233-544) protein was expressed in DH10B cells and purified
according to the standard protocol of Amersham Pharmacia Biotech,
Uppsala, Sweden (GST gene fusion system, 3rd edition). Buffers for
GST-Cdc42 purification contained 1 µM GDP starting from
the lysis, excluding the dialysis buffer. The GST moiety was cleaved
off the Cdc42 with thrombin at a final concentration of 10 units/ml
glutathione beads. Thrombin was removed by incubation with
p-aminobenzamidine beads (Sigma) and Cdc42 dialyzed four times against buffer (25 mM Tris/HCl, pH 7.5, 1 mM EDTA, 5 mM MgCl2, 1 mM DTT, 0.1 mM phenylmethylsulfonyl fluoride).
After dialysis, 1 µM GDP was added again and the purified
protein was concentrated by ultrafiltration.
His-tagged fusion proteins in vector pET28a were expressed in BL21/DE3
(pLysS). The recombinant kinase fragment (hpak1-(232-545)) was
purified following the standard batch purification protocol under
native conditions (Qiagen QIAexpressionist, March 1997). The
histidine-tagged fusion proteins, hpak1-(1-234) and hpak1-(67-150), were purified under denaturing conditions according to the batch purification method by Qiagen. After elution the proteins were dialyzed
twice against 2 liters of buffer (50 mM Hepes/NaOH, pH 7.5, 100 mM NaCl, 10 mM MgCl2, 5%
glycerol) and stored frozen at Binding Assay--
Rat Pak1 kinase fragment (amino acids
233-544) fused to glutathione S-transferase
(GST-rpak1-(233-544)) and an NH2-terminal His6/T7-tagged fusion of human Pak1 hpak1-(1-235) were
purified and used for in vitro binding studies. The rat Pak1
COOH-terminal kinase domain does not differ in amino acid sequence from
the human homologue (sequencing of human Pak1 revealed that amino acid
503 in human Pak1 is glutamic acid, codon GAG, and not aspartic acid,
codon GAT, as in the GenBank data base sequence). 1-5 µg of
GST-rpak1-(233-544) kinase domain was incubated with 1-3 µg of
NH2-terminal protein fragments in binding buffer (50 mM Hepes/NaOH, pH 7.5, 100 mM NaCl, 10 mM MgCl2, 1 mM DTT, 1% Nonidet
P-40) in a volume of 200-500 µl. To immobilize the GST protein,
glutathione-agarose beads equilibrated in binding buffer were added to
the reaction and incubated for 30 min to 1 h at 4 °C under
constant agitation. Binding reactions were washed four times with 1 ml
of binding buffer each. Samples were boiled in SDS-sample buffer and
separated on SDS-PAGE gels for immunoblotting or Coomassie staining.
In Cdc42 competition experiments, the binding reactions were washed
twice with binding buffer to remove unbound hpak1-(1-234) and Cdc42
was added to the complex for 15 min on ice or for 15 min at 30 °C as
indicated in the figure legends. The bead fraction was washed again
four times with binding buffer and prepared for SDS-PAGE.
Transfections and Immunoprecipitations--
Cos-1 or HeLa cells
were seeded on 10 cm cell culture dishes at 50-70% confluency and
transfected using LipofectAMINE (Life Technologies, Inc.) as a
transfection agent. 5 µg of plasmid DNA and 15 µl of LipofectAMINE
were used per dish, and the transfection protocol was essentially
followed according to the manufacturer's guidelines (Life
Technologies, Inc.). After 48 h the dishes were washed once with
1× Hanks' buffered saline solution (Life Technologies, Inc.) and
lysed in 0.5 ml of lysis buffer (25 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1 mM
EGTA, 1 mM DTT, 10% glycerol, 1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride). The expression of
proteins in the lysates was analyzed by immunoblotting. For precipitations of myc-tagged hPak1, lysates were incubated with equilibrated protein G beads and monoclonal anti-myc antibody (9E10)
for at least 3 h or overnight at 4 °C. The bead fraction was
washed four times with lysis buffer, stored frozen at Loading of Cdc42 and Preparation of Sphingosine--
Cdc42 was
loaded with GTP
Sphingosine was dissolved in 95% ethanol at a concentration of 15 mM and stored at In Vitro Kinase Assays--
Kinase reactions with purified
recombinant or immunoprecipitated Pak were performed in kinase buffer
(50 mM Hepes/NaOH, pH 7.5, 10 mM
MgCl2, 2 mM MnCl2, 0.2 mM DTT) in a volume of 60 µl with 250 µM
ATP except for the experiment shown in Fig. 1D, where 50 µM ATP was used. Radiolabeled ATP was used at 10 µCi/reaction. The reactions were incubated for 30 min at 30 °C and
stopped by addition of sample buffer. Myelin basic protein (MBP) was
used as a substrate at 2-4 µg/reaction.
To prephosphorylate Pak prior to a kinase reaction, the protein G-bound
hPak1 was incubated with 250 µM unlabeled ATP and an
activator (0.5-2 µg of GTP Interaction between the Pak1 Kinase Domain and a
NH2-terminal Region--
Pak kinases consist of a
NH2-terminal regulatory domain and a COOH-terminal kinase
domain having many of the conserved features of all known
serine/threonine kinases. Several lines of evidence have suggested that
the NH2-terminal region down-regulates the enzymatic
activity of the COOH-terminal kinase. We tested whether we could detect
a physical interaction between these domains that might be responsible
for inhibiting Pak kinase activity.
As seen in Fig. 1A, the
purified hpak1-(1-234) fragment efficiently complexed with the
bead-coupled GST-rpak1-(233-544) COOH-terminal piece containing the
entire kinase domain. Binding was specific to the GST-rpak1-(233-544)
fusion since the amino terminus was not precipitated with GST alone.
Incubating the preformed GST-rpak1-(233-544)/NH2 terminus
complex with GTP
Cdc42 binds Pak1 in a minimal region consisting of amino acids 75-89
(14). However, amino acids surrounding this sequence contribute to the
efficiency of the interaction (9). We hypothesized, based on the Cdc42
competition experiments (Fig. 1), that the domain interacting with the
kinase core might be in close vicinity or overlap with the Cdc42
binding site. To localize the carboxyl-terminal interacting and
autoinhibitory domain in the NH2 terminus, we expressed
smaller regions of human Pak1 as recombinant His6/T7-tagged proteins in Escherichia coli and tested these in pull-down
assays with GST-rpak1-(233-544) immobilized on glutathione-agarose. We detected a very efficient interaction with a His6/T7-tagged
fusion of the wild type hpak1-(67-150) peptide (Fig.
2A, lane
4). The amino-terminal fragment did not bind to the GST
protein (Fig. 2A, lane 3),
demonstrating the specificity of this interaction. Other amino-terminal
Pak fragments (amino acids 1-74 and 174-306) were not pulled down by
the COOH-terminal fragment (data not shown). The region encompassing
amino acids 67-150 contains the previously characterized
GTPase/p21-binding domain and confirmed our hypothesis that the
interaction site is in close proximity to the p21 binding domain. To
further refine the interacting region, we constructed smaller peptides
of hPak1 (aa 67-89, 67-108, and 109-150). However, we could not
detect an interaction of these peptides with the Pak1 kinase domain
using the pull-down assay (data not shown).
We employed already characterized mutations within hpak1-(67-150) to
further analyze the function of this region. Mutation of both conserved
histidine residues to leucine (H83L,H86L) has been shown to disrupt the
interaction with small GTPases, accompanied by a moderate increase in
kinase activity (13, 15). Mutating leucine 107 to phenylalanine, on the
other hand, leads to strong activation of full-length Pak1, and
activity is independent of GTPases (16), even though binding is
maintained. We analyzed how these mutations influence the interaction
with the GST-rpak1-(233-544) fusion. As seen in Fig. 2A
(lanes 5-12), the H83L and H86L single and
double mutants bound as efficiently to the kinase domain as did the
wild type peptide. In contrast, the L107F mutation exhibited drastically reduced binding to the kinase domain.
The purified hpak1-(67-150) fragments had different abilities to
inhibit GST-rpak1-(233-544) kinase (Fig. 2B). The wild type hpak1-(67-150) was most potent in inhibiting kinase activity, whereas
the L107F mutated peptide was strongly reduced in its inhibitory
potency, and the H83L,H86L double mutant was moderately reduced in
inhibiting GST-rpak1-(233-544) kinase activity. The hpak1-(67-150)
fragments, unlike hpak1-(1-234), were not phosphorylated substantially. We termed the hpak1-(67-150) region PBD/ID
(p21 binding
domain/inhibitory domain).
Influence of hpak1-(67-150) Peptides on Cdc42-stimulated hPak1
Kinase Activity--
Using GST- rpak1-(233-544) kinase to evaluate
the inhibitory potential of the PBD/ID region (aa 67-150) had the
advantage that the isolated COOH terminus is constitutively active,
independently of GTPases. However, we asked whether Cdc42-stimulated
hPak1 activity could also be inhibited by the purified peptides. Since
a functional p21 binding site is contained within the PBD/ID fragment,
it was expected that inhibition of kinase activity could in part be due to sequestering of the GTPases. The ability of the PBD/ID fragments to
bind activated Cdc42 was tested (Fig. 3).
Only the wild type fragment and the L107F mutated form could bind Cdc42
in overlay assays, although the latter bound with somewhat reduced
affinity (about 50% of wild type). Mutation of histidines 83 and 86 either separately or together led to a complete loss of binding to
Cdc42. Any kinase inhibition by these Cdc42 binding-deficient fragments would therefore not be due to titration of GTPases.
We were able to show that not only the Cdc42-binding proficient, but
also the binding-deficient versions were able to inhibit full-length
hPak1 activity. As Fig. 4A
shows, both autophosphorylation and substrate phosphorylation are
reduced by hpak1-(67-150) peptides. The wild type and L107F mutant
peptides strongly reduce kinase activity. The inhibition by the L107F
peptide is most likely due to sequestration of the activated Cdc42. Of
the GTPase binding-deficient versions, the H83L mutant peptide was most
potent in its kinase-inhibitory effect. Mutation of position 86 significantly reduced the inhibitory effect to a similar extent as did
the H83L,H86L double mutant. All peptides showed
concentration-dependent inhibitory effects. We titrated the
H83L peptide to determine the half-maximal inhibitory concentration
using a constant amount of immunoprecipitated hPak1 stimulated with
Cdc42 (Fig. 4B). The purified peptides were not significantly phosphorylated and therefore did not interfere with the
Ki determination. We calculated the apparent
Ki as 1.2 µM for MBP phosphorylation
(Fig. 4C). Overall, the peptide inhibition data obtained
with p21-activated Pak1 fit well with those using GST-rpak1-(233-544)
(Fig. 2C). Taken together, these data demonstrate that the
functional domains for p21 binding and autoinhibition of kinase
activity overlap in part within the PBD/ID. Both activities can,
however, be separated from each other, demonstrating that the PBD and
the ID have distinct structural determinants for function.
Effect of Autophosphorylation on Inhibition by the ID
Domain--
Pak kinases autosphosphorylate after stimulation with
activated Cdc42 and remain activated after removal of the GTPase (17). In light of our above results, this could indicate that phosphorylation events antagonize the inhibitory effect of the ID domain by decreasing its interaction with the kinase domain. Full-length hPak1 was activated
by autophosphorylation for 30 min in the presence of excess unlabeled
ATP and Cdc42-GTP
Interestingly, a hPak1 mutant, hPak1-(T423E) (13), which is
constitutively activated by mutation at phospho-acceptor site threonine
423 in the activation loop, is also completely inert toward inhibition
by the PBD/ID fragments (Fig. 5B). In this case, both
autophosphorylation and substrate phosphorylation are not affected by
the hpak1-(67-150) peptide. This argues that the phosphorylation state
of threonine 423 is a critical determinant for kinase inhibition by the
ID domain.
Importance of Threonine 423 for Kinase Activity and
Autoinhibition--
As indicated by the threonine 423 to glutamic acid
mutation in hPak1, the phosphorylation status of the activation loop
appears to be of importance for the autoinhibitory mechanism. To
analyze this in more detail, we constructed a threonine 423 to alanine mutant that does not autophosphorylate at this residue, and the activity of this mutant was compared with the wild type protein in
in vitro kinase assays.
Basal activities of immunoprecipitated T423A hPak1 did not differ from
wild type (Fig. 6, lanes
1 and 6). The Cdc42-stimulated hPak1 T423A had a
decreased activity toward exogenous substrate, ranging from 10 to 30%
of wild type activity (Fig. 6, compare lanes 2 and 7). Autophosphorylation was less affected and in the range of 40-60% of wild type Pak1. The Cdc42-stimulated hPak1-(T423A) activity was sensitive to inhibition by the H83L hpak1-(67-150) fragment. Prephosphorylation of hPak1-(T423A) in the presence of
GTP Sphingosine-mediated Activation of hPak1 and Influence on
PBD/ID-mediated Inhibition--
It was of interest to analyze if
lipid-mediated activation of hPak1 is sensitive to the ID/kinase domain
interaction. Sphingosine, which is one of the more effective lipids to
activate hPak1 (11), was used in in vitro kinase assays in
the absence and presence of the PBD/ID peptide (Fig.
7). The concentration (400 µM) used in the assay resulted in a highly activated
hPak1 in which auto- and substrate phosphorylation was comparable to
the Cdc42-stimulated enzyme (Fig. 7A). Under these
conditions, sphingosine-mediated activation was completely insensitive
to the wild type PBD/ID fragment. However, we observed that activation
of hPak1 with non-saturating concentrations (50 µM) of
the lipid was reduced by the wild type hpak1-(67-150) peptide (Fig.
7B). Prephosphorylation of hPak1 in the presence of
sphingosine led (as shown for activation by Cdc42) to an increased
activity in the absence of the primary stimulus (Fig. 7A,
lane 9). Sphingosine-mediated autophosphorylation is therefore sufficient to maintain Pak1 activity. In this case, where
lipid was washed out after the initial incubation, the
autophosphorylated activated species could clearly be shown to be
unresponsive to high concentrations of the purified PBD/ID
fragment (Fig. 7A, lane 10).
Activator-induced Opening of the Kinase Results in Exposure and
Subsequent Phosporylation of Threonine 423--
Autophosphorylation of
hPak1 by sphingosine or GTPases results in increased kinase activity
that is maintained even in the absence of the primary stimulus (Fig.
7A). This raised the question whether phosphorylation of
hPak1 by another active Pak1 molecule (intermolecular phosphorylation)
could be sufficient for activation in the absence of stimulators
(GTPase, lipids).
We used recombinant His6/T7-tagged hpak1-(232-545) kinase
to phosphorylate wild type human Pak1. The hpak1-(232-545) kinase fragment phosphorylated the full-length form of hPak1 overexpressed in
Cos-1 cells (Fig. 8A,
middle panel). Although the recombinant kinase
fragment was highly active toward substrates (MBP, full-length hPak1),
we were not able to see it autophosphorylate (Fig. 8, left
panel), possibly due to prior autophosphorylation in
E. coli (data not shown). However, intermolecular
phosphorylation of full-length hPak1 did not result in, and therefore
might not be sufficient for, activation (Fig. 8A,
right panel).
Further evidence suggested that the key phosphorylation site threonine
423 is protected from intermolecular phosphorylation when full-length
Pak1 is in an inactive conformation. A phosphospecific antiserum
specifically detecting the threonine 423 phosphorylated form of the
subdomain VIII activation loop showed that threonine 423 was not
phosphorylated by the recombinant hpak1-(232-545) kinase (Fig.
8B, lane 7), whereas this antiserum
efficiently detects the threonine 423-phosphorylated species of wild
type hPak1 stimulated with Cdc42 or sphingosine (Fig. 8B,
lanes 2 and 3). In this experiment the
kinase-inactive hPak1-(K299A) was used to investigate the role of
activator binding on threonine 423 phosphorylation (Fig. 7C,
lanes 4-9). Indeed, if GTP
These data suggest that the conformational status of Pak1 determines
the accessibility of threonine 423 for intermolecular phosphorylation.
In the closed conformation (absence of activators), this residue is not
accessible. Opening of the Pak1 structure by activators eliminates
these conformational restraints and leads to exposure of threonine 423 for phosphorylation. The fact that both activators qualitatively give
the same results again argues that sphingosine action on the Pak1
molecule is virtually equivalent to that of Cdc42.
Mechanistic Model of Pak Activation--
The data presented here
suggest the following model for the regulation of Pak kinase activity
(Fig. 9A). A key feature in the control of Pak enzymatic activity is a regulated interaction between an amino-terminal inhibitory domain and the catalytic kinase
domain. Cdc42 and Rac GTPases that are in the active GTP-loaded conformation bind to the amino-terminal PBD and disrupt this
interaction, thereby relieving initial inhibition of the kinase.
Binding of the GTPase to Pak is a reversible event, i.e.
when the GTPase drops off, the inhibitory mechanism can engage again
and silence the kinase as long as no autophosphorylation occurs.
Phosphorylation of the kinase domain at threonine 423 in the activation
loop in subdomain VIII renders the enzymatic activity insensitive to
the autoinhibitory module, possibly reflecting the inability of the
inhibitory module to interact with the kinase domain. At this stage,
the dissociation of the GTPase from Pak is no longer sufficient to
inhibit enzymatic activity; instead, dephosphorylation has to occur to
enable Pak to refold and engage the inhibitory module.
However, our data indicate that phosphorylation of threonine 423 serves
a dual purpose, as it is also required to achieve full kinase activity.
This appears to be similar to the mechanism described for protein
kinase A, in which phosphorylation of the equivalent threonine
positions the activation loop to allow better substrate access in the
groove between the two lobes of the enzyme structure (19).
Pak Activation by GTPases/Lipids--
How does GTPase binding
interfere with the intramolecular interaction within the Pak molecule?
In our studies, we could localize the interacting and autoinhibitory
domain in the amino terminus to amino acids 67-150 of human Pak1. This
region contains also contains the p21-binding domain. The minimal
requirement for GTPase binding that has been defined by Burbelo
et al. (14) spans amino acids 75-89 of human Pak1. However,
it has been shown that amino acids both amino- and carboxyl-terminal of
the minimal site enhance the binding affinity to the GTPases (9). We
established, using previously characterized amino acid substitutions in
Pak1, that both domains overlap but are at least partially separable.
Mutating histidine 83 to leucine resulted in a drastic loss of
Cdc42-binding, whereas this mutant still efficiently inhibited Pak1
kinase activity. On the other hand, mutation of leucine 107 to
phenylalanine, previously demonstrated to activate full-length Pak1
kinase, maintained effective binding to GTPases but prevented
interaction with the kinase domain. Histidine 86 is a key residue for
both GTPase binding and autoinhibition. While this mutation seems not
to affect the interaction with the kinase domain, as indicated by our
GST pull-down assay, histidine 86 does make a functionally important
contact required for inhibition of the Pak kinase core. Histidine 86 thus defines an overlapping site encompassing the end of the GTPase
binding domain and the start of the autoinhibitory domain. The close
proximity between the GTPase-binding and autoinhibitory domains
suggests a simple model for the opening of the Pak structure. Binding
of the GTPase to the PBD/ID interferes with functionally important
regions of the autoinhibitory module and consequently separates the
intramolecular interaction.
We propose that stimulating lipids, like sphingosine, induce Pak kinase
activation in a similar fashion as small GTPases. Indeed, previous
observations (11) suggested that the lipid interaction domain is also
located (at least in part) within the characterized PBD/ID region.
Sphingosine action on hPak1 leads to phosphorylation of threonine 423, as does activated GTPase. We therefore believe that sphingosine
interferes with the autoinhibitory module leading to opening of the Pak
structure. We have been unable to show that sphingosine disrupts the
interaction in our established pull-down assay, however, probably due
to the need to use non ionic detergents to prevent unspecific binding
of the amino-terminal fragments (hpak1-(1-234), hpak1-(67-150)) to
glutathione-agarose. The presence of the detergents destroys lipid
vesicle formation necessary for sphingosine to act properly.
Zhao et al. (9) have recently described an autoinhibitory
region by in vitro kinase assays in rat alpha Pak, which is
the rat homologue of human Pak1. Rat and human Pak1 are more than 98%
identical and differ only at seven amino acid positions located in the
NH2-terminal regulatory region. Consistent with the
autoinhibitory function described, we characterized the inhibitory
domain in biochemical interaction assays using recombinant proteins.
Zhao et al. (9) identified an autoinhibitory region from
amino acid 83 to 149 that is contained within our minimal inhibitory
region spanning amino acids 67-150 (the numbering of amino acids
between rat
Most of the Pak-homologous kinases, in addition to the minimal GTPase
binding domain, exhibit sequence homologies in the immediate carboxyl-terminal region where determinants for the autoinhibitory module are located, suggesting that the described mechanism of kinase
inhibition/activation is conserved within the Pak kinase family.
Interestingly, a recently isolated and characterized Pak isoform, Pak4,
shows constitutive kinase activity, independent of the binding of
GTPases. Pak4 contains a p21-binding domain, but does not share
homology in the carboxyl-terminal portion of this region where
determinants for the inhibitory domain are located (21).
Threonine 423 in the Activation Loop as a Key Regulatory
Site--
Phosphorylation of threonine 423 seems to be a key event for
full activation of Pak1 and maintaining the kinase in a catalytically competent state. Studies on Pak65 (4) suggested that
autophosphorylation of the kinase domain results from inter- and not
intramolecular phosphorylation events. For protein kinase A, it has
been proposed that phosphorylation within the activation loop might
occur through an intermolecular mechanism (19). Due to its position and
proximity to the catalytic center, we consider it unlikely that
threonine 423 can be phosphorylated in cis (Fig.
9B). Although we cannot fully exclude this possibility, we
were able to show that threonine 423 is accessible for intermolecular phosphorylation.
Our intermolecular phosphorylation studies showed that threonine 423 is
not accessible in the closed Pak structure (Fig. 9B). Threonine 423 was only phosphorylated in Pak1-(K299A) when activated GTPase or sphingosine were added, indicating that opening of the Pak
structure is required to make threonine 423 accessible for intermolecular phosphorylation. Whether the autoinhibitory module physically masks threonine 423 from phosphorylation or whether it
induces a structural change in the kinase domain as depicted in the
model in Fig. 9B is not clear.
Intermolecular phosphorylation only occurs if the Pak molecules are
bound to activators. We envision this as a mechanism to spatially
regulate Pak activation inside the cell, for example to areas where
GTPases are localized. Inactive Pak molecules not interacting with
GTPases/lipids cannot be activated by intermolecular phosphorylation,
thereby preventing an undesirable chain reaction of Pak activation.
We thank Erica M. Dutil and Alexandra C. Newton for their excellent phosphospecific anti-PKC *
This work was supported in part by National Institutes of
Health Grants GM 39434 and AG15430 (to G. M. B.). This is
publication 12434-IMM from the Scripps Research Institute.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Recipient of a postdoctoral fellowship from the National Arthritis Foundation.
¶
To whom correspondence should be addressed:
Immunobiology-IMM14, Scripps Research Inst., 10550 N. Torrey Pines Rd.,
La Jolla, CA 92037.
The abbreviations used are:
Pak, p21-activated
kinase;
GST, glutathione S-transferase;
ID, inhibitory
domain;
MBP, myelin basic protein;
PBD, p21-binding domain;
PAGE, polyacrylamide gel eletrophoresis;
DTT, dithiothreitol;
GTP
Identification of a Central Phosphorylation Site in p21-activated
Kinase Regulating Autoinhibition and Kinase Activity*
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]ATP (specific activity 4500 mCi/mmol) was from
ICN, Costa Mesa CA. Plasmids for transfection were purified using the
Qiafilter purification system of Qiagen, Chatsworth CA. The T7-tag
monoclonal antibody was purchased from Novagen, Madison WI. Thrombin
and sphingosine were purchased from Sigma; GTP
S and
[35S]GTP
S were from NEN Life Science Products. For
polymerase chain reactions, the Expand High Fidelity PCR system from
Roche Molecular Biochemicals was used. The PKC
II antibody
(originally raised against a subdomain VIII phosphopeptide of the
protein kinase C isoform
II, kindly provided by Erica Dutil and
Alexandra Newton, University of California, San Diego, CA) was used to
detect the threonine 423 phosphorylated subdomain VIII activation loop
of Pak1.
70 °C.
70 °C, or
directly used for kinase assays. To use immunoprecipitated hPak1 in
kinase assays, the bead fraction was washed twice in kinase buffer.
S under the following conditions. 5-20 µg of Cdc42
were incubated in 25 mM Hepes/NaOH, pH 7.5, containing 20 mM EDTA and 1 mM GTP
S for 10 min at 30 °C
in a total volume of 25-100 µl. The reaction was stopped by addition
of MgCl2 at 100 mM final concentration.
20 °C. Aliquots were dried under
nitrogen gas and dissolved in 25 mM Tris/HCl, pH 7.5, at
3-4 mM concentration. Before addition of sphingosine to
the kinase reaction, the lipid solution was sonicated for 30-60 s.
S-loaded Cdc42 or 0.4 mM
sphingosine) for 30 min at 30 °C. The reactions were washed three
times with lysis buffer and twice with kinase buffer and directly used
in kinase assays as described above.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
S-loaded Cdc42 reduced the amount of the
hpak1-(1-234) in the pull-down fraction (Fig. 1A,
lane 4). This reduction was specific for
GTP
S-loaded Cdc42, as a GDP-loaded or a non-loaded Cdc42 was not
able to compete (Fig. 1B). Addition of GTP
S-loaded Cdc42
decreased complex formation in a concentration-dependent manner (Fig. 1C). A hpak1-(1-234) fragment in which the
Cdc42-binding site was mutated (H83L,H86L) bound as efficiently as the
wild type fragment to the kinase domain (Fig. 1C, compare
lanes 2 and 7). However, in this case
the GTP
S-loaded Cdc42 was not able to disrupt the interaction,
indicating that binding of the GTPase to the NH2-terminal
fragment is required for the observed competitive effect. In
vitro kinase assays showed hpak1-(1-234) is capable to inhibit
GST-rpak1-(233-544) kinase activity (Fig. 1D,
lanes 3-6). With increasing amounts of the
NH2 terminus, autophosphorylation and phosphorylation of
myelin basic protein were decreased. However, hpak1-(1-234) itself was
a good substrate for GST-rpak1-(233-544) (data not shown) and this,
due to competitive substrate phosphorylation, made it difficult to
determine the Ki value.

View larger version (28K):
[in a new window]
Fig. 1.
Interaction between the amino-terminal
hpak1-(1-234) fragment and the carboxyl-terminal Pak1 kinase domain
and inhibition of kinase activity. A, 10 µg of
glutathione S-transferase (GST) or the GST-rpak1-(233-544)
fusion protein coupled to glutathione-agarose beads was incubated with
10 µg of the NH2-terminal His/T7-tagged hpak1-(1-234) in
150 µl of binding buffer for 15 min at 4 °C. The bead fraction was
washed twice in binding buffer and then incubated with 10 µg of
GTP
S-loaded Cdc42 (lanes 2 and 4)
on ice. Binding reactions were washed again, and half of the reaction
was electrophoresed on a 10% SDS-polyacrylamide gel. The
Coomassie-stained gel is shown. B, 5 µg of GST or
GST-rpak1-(233-544) bound to glutathione-agarose beads was incubated
with 7.5 µg of hpak1-(1-234) in 130 µl of binding buffer as
described under A. 5 µg of GTP
S- or GDP-loaded or
unloaded Cdc42 was incubated with the bead-bound fraction, the beads
were washed, and proteins separated by SDS-PAGE. The NH2
terminus was immunodetected with the T7 tag antibody. C,
binding conditions as in B. The indicated amounts of
GTP
S-loaded Cdc42 were incubated with the bead-bound proteins for 15 min at 30 °C. The washed bead-bound fraction was separated by
SDS-PAGE and immunodetected with the T7 tag antibody. Note that two
hpak1-(1-234) bands are detected in C due to residual
thrombin activity in the Cdc42 preparation. D,
hpak1-(1-234) inhibits GST-rpak1-(233-544) kinase activity. A
constant amount of GST-rpak1-(233-544) (1 µg) was preincubated with
the indicated amounts of hpak-(1-234), dialysis buffer
(lane 7), or 6 µg of bovine serum albumin
(lane 8), and a kinase reaction was performed.
Adenosine triphosphate was used at 50 µM concentration,
myelin basic protein at 2 µg/reaction. An autoradiograph of the
electrophoresed kinase reactions is shown. Note that, on this and
subsequent figures, fragment numbers are given as
superscripts.

View larger version (21K):
[in a new window]
Fig. 2.
Interaction of the GST-rpak1-(233-544)
kinase domain with hpak1-(67-150) and inhibition of kinase
activity. A, upper panel, the
His6/T7-tagged amino-terminal fragments hpak1-(67-150)
(wild type (wt) and mutants indicated by amino acid change
introduced and its position) were purified by denaturing chromatography
on Ni-NTA. As a control, an eluate from control vector (pET28a)
expressing E. coli was purified and used in binding
experiments and kinase reactions (lane 1). Shown
are the electrophoresed peptides (normalized for protein) used in the
binding assay below. Lower panel, 5 µg of GST
or 2.5 µg of GST-rpak1-(233-544) was incubated with 1.2 µg of the
indicated hpak1-(67-150) proteins and glutathione-agarose beads for
1 h at 4 °C and washed four times with binding buffer. Binding
reactions were resolved on a 13% SDS-polyacrylamide gel. The Ponceau
S-stained GST and GST-rpak1-(233-544) are shown in the
upper panels. The hpak1-(67-150) and mutated
fragments recovered in the bead fraction were detected with the T7 tag
antibody. B, a kinase assay was performed using
GST-rpak1-(233-544) (0.5 µg/reaction) in the presence of the
indicated hpak1-(67-150) peptides. The purified peptides were used at
1 and 2 µM concentration, respectively, in the kinase
assay. The phosphorylated GST-rpak1-(233-544) and MBP are labeled on
the autoradiograph.

View larger version (22K):
[in a new window]
Fig. 3.
Binding of activated Cdc42 to hpak1-(67-150)
and its mutated derivatives. The His/T7-tagged amino-terminal
peptides (aa 67-150) were normalized and separated by SDS-PAGE on a
13% polyacrylamide gel. The upper panel shows
the Ponceau S-stained hpak1 peptides blotted onto the membrane. The
blotted proteins were subjected to a GTPase-overlay assay as has been
described (20). The immobilized proteins were incubated with
[35S]GTP
S-labeled Cdc42 and the bound GTPases were
visualized by autoradiography (lower
panel).

View larger version (36K):
[in a new window]
Fig. 4.
Inhibition of Cdc42-stimulated full-length
hPak1 activity by hpak1-(67-150) peptides. A,
normalized concentrations of the indicated hpak1-(67-150) peptides
were used for this kinase assay as shown in the Coomassie-stained gel
(upper panel). Immunoprecipitated wild- type
hPak1 was used at a constant amount per reaction, and the purified
hpak1-(67-150) peptides were added at final concentrations of 2 and 4 µM. 1.25 µg of GTP
S-loaded Cdc42 was added to the
reactions as indicated. Kinase reactions were performed in the presence
of 250 µM ATP with 4 µg of MBP as a substrate. The
middle panel shows an autoradiograph of the
electrophoresed kinase reactions. Phosphorylated hPak1 and myelin basic
protein are labeled. A quantification of the PhosphorImager data is
presented in the lower panel. As a reference
Cdc42-stimulated auto- and substrate phosphorylation (lane
2) were set to 100%. B, a constant amount of
immunoprecipitated wild type hPak1 was assayed in the presence of
increasing concentrations of H83L hpak1-(67-150) (0.4, 1, 2, 4, and 8 µM final; lanes 8-12) or the
control eluate (lanes 3-7, see legend of Fig.
2). A constant amount of GTP
S-loaded Cdc42 (0.7 µg/reaction) was
added to the kinase reaction as indicated. Myelin basic protein was
used at 4 µg/reaction. C, graphic representation of the
phosphorimaging data shown in B. Cdc42-stimulated MBP
phosphorylation by wild type hPak1 (see B, lane
2) was set to 100%. The concentration to get half-maximal
inhibition was calculated to 1.2 µM.
S; these were then removed by washing (Fig.
5A). As shown in
lanes 3-7, in a subsequent kinase reaction with
labeled ATP the incorporation of label into hPak1 was drastically
decreased due to an efficient incorporation of unlabeled ATP in the
initial reaction. Autophosphorylated hPak1 was highly active toward
substrate even without further addition of activated Cdc42. The
hpak1-(67-150) wild type peptide and also the mutated versions (data
not shown) did not affect substrate phosphorylation activity of the
autophosphorylated Pak1 at levels sufficient to efficiently block
Cdc42-stimulated hPak1. Addition of activated GTPase to
prephosphorylated hPak1 did not restore the sensitivity toward
ID-mediated inhibition (data not shown). We also observed that the
hPak1 kinase domain (aa 232-545), when expressed as a His6/T7-tagged
fusion protein in E. coli, is autophosphorylated and also
not inhibited by excess concentrations of PBD/ID peptide (data not
shown), supporting the idea that phosphorylation renders the kinase
domain independent of autoinhibition.

View larger version (31K):
[in a new window]
Fig. 5.
Prephosphorylated hPak1 and hPak1-(T423E) are
not inhibited by the PBD/ID peptides. Upper
panel, immunoprecipitated wild type hPak1 was
prephosphorylated in the presence of GTP
S-loaded Cdc42
(lanes 3 and 7) and used in kinase
reactions in comparison to untreated hPak1 (lanes
1 and 2). The amount of immunoprecipitated hPak1
was kept constant in all reactions. 1.5 µg of Cdc42 was added to the
kinase (lane 2) and prephosphorylation reactions
(lanes 3-7). Control Ni-NTA eluate (buffer
control, co) or wild type hpak1-(67-150) (2 and 4 µM, wt) was added to the reactions. hPak1 and
MBP signals are indicated. Lower panel, a
constant amount of immunoprecipitated hPak1-(T423E) was used per kinase
reaction. Control Ni-NTA eluate and wild type hpak1-(67-150) peptide
(2 and 4 µM) were added as indicated.
S-loaded Cdc42 and excess cold ATP led to a significant decrease
in the incorporation of radioactivity into the protein in a subsequent
kinase reaction. The prephosphorylated hPak1-(T423A) retained its
(reduced) activity toward substrate but surprisingly this activity was
still sensitive toward addition of hpak1-(67-150) fragment (Fig. 6,
lane 10).

View larger version (63K):
[in a new window]
Fig. 6.
Phenotype of the threonine 423 to alanine
mutation in hPak1. Wild type hPak1 and hPak1-(T423A) were
immunoprecipitated from Cos-1 lysates and protein levels were
normalized prior to the kinase assay. 1.5 µg of Cdc42 loaded with
GTP
S was added to prephosphorylation and kinase reactions as
indicated. MBP was used as a substrate at 4 µg/reaction. The
H83L-hpak1-(67-150) peptide was used at 6 µM
concentration. The autoradiograph of the electrophoresed kinase
reactions is shown in the upper panel, the
PhosphorImager quantification is shown in the lower
panel. Residual thrombin activity in the Cdc42 preparation
resulted in cleavage of myelin basic protein (labeled with * in the
autoradiograph). As reference, Cdc42-stimulated wild type hPak1
activity toward MBP was set to 100%. Note that hpak1-(67-150) was
phosphorylated (lane 5).

View larger version (29K):
[in a new window]
Fig. 7.
Influence of sphingosine on PBD/ID-mediated
inhibition. Wild type hPak1 was used at a constant amount in all
kinase reactions. A, hPak1 was prephosphorylated with
unlabeled ATP in the presence of 1 µg of GTP
S-loaded Cdc42
(lanes 4 and 5) or 400 µM sphingosine (lanes 9 and
10). The same concentration of activators was used in the
kinase reactions with untreated hPak1 as indicated. The hpak1-(67-150)
peptide was used at 4 µM final concentration
(lanes 3, 5, 8, and
10). The autorad is presented in the upper
panel; the PhosphorImager quantification is shown
below. Note, that due to traces of thrombin-activity in the
Cdc42 preparation, a fraction of MBP was cleaved into two smaller
fragments in lane 2 (labeled with *). Phosphate
incorporation into these cleaved fragments was included in the
PhosphorImager quantification. Phosphorylation of MBP in
lane 2 was set to 100%. B, kinase
assay using wild type hPak1 stimulated with the indicated
concentrations of sphingosine or 1 µg of Cdc42 in the presence and
absence of 4 µM wild type hpak1-(67-150).

View larger version (26K):
[in a new window]
Fig. 8.
Intermolecular phosphorylation of hPak1.
A, a kinase reaction was performed using recombinant and
kinase active hpak1-(232-545) to phosphorylate full-length human Pak1
in Cos1 lysates. Left panel, kinase assay with
hpak1-(232-545) in the presence and absence of MBP. Middle
panel, a kinase reaction was performed using lysates from
Cos-1 cells expressing control vector or wild type hPak1. The
hpak1-(232-545) kinase fragment was added to the reactions as
indicated. Right panel, immunoprecipitated wild
type hPak1 was prephosphorylated in the presence and absence of
hpak1-(232-545), washed, and subjected to a kinase assay using MBP as
a substrate. The activity toward MBP of the amount of hpak1-(232-545)
used for cross-phosphorylation is shown on the right.
B, phosphorylation of threonine 423 by hpak1-(232-545).
Immunoprecipitated wild type and kinase inactive hPak1-(K299A) were
incubated with 1 µg of GTP
S-loaded Cdc42 and 400 µM
sphingosine as indicated. hpak1-(232-545) was added to the reactions
as indicated. 250 µM ATP was present in all reactions.
The reactions were incubated for 30 min at 30 °C, then separated on
a 12% SDS-polyacrylamide gel and blotted for immunodetection using an
antiserum recognizing the threonine 423-phosphorylated activation loop
of hPak1. Upper panel, the Ponceau S-stained
hPak1 proteins are shown. Wild type hPak1 showed significant decrease
in mobility after phosphorylation with GTP
S-loaded Cdc42 or
sphingosine. Lower panel, immunodetection of
threonine 423 phosphorylation using the alkaline phosphatase color
reaction.
S-loaded Cdc42 or
sphingosine were added together with the recombinant pak1-(233-544)
kinase to hPak1-(K299A), then threonine 423 was phosphorylated.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (31K):
[in a new window]
Fig. 9.
Model for the regulation of p21-activated
kinase. A, left upper
panel, Pak kinases exist in a closed conformation in the
absence of an activator (GTPase, lipid) due to an interaction between
the ID and the kinase domain (KD). The conformationally
closed Pak has a basal level of kinase activity. Right
upper panel, binding of activators (GTPase,
sphingosine) leads to a conformational change to open the Pak
structure, relieving the initial inhibitory constraints. (Our data
suggest that binding of the lipid occurs within the PBD/ID region, but
the binding requirements have not been defined yet). However, binding
of the activators disrupts the ID-kinase domain interaction due to an
overlap of their binding sites. The opened and unphosphorylated Pak has
increased activity toward substrate. Right lower
panel, as a consequence of increased kinase activity, Pak
autophosphorylates at several residues, including threonine 423, which
leads to a maximal increase in the enzymatic activity. Left
lower panel, even if the activator dissociates
from its binding site, Pak kinase activity remains high, since
phosphorylation of threonine 423 and possibly serine/threonine residues
in the inhibitory domain keep the kinase in an open and highly active
conformation. Dephosphorylation has to occur to switch Pak back to the
closed and inactive conformation. B, opening of Pak leads to
intra- and intermolecular autophosphorylation. Left
panel, threonine 423 in the activation loop of the kinase
domain is not accessible for intermolecular phosphorylation when the
Pak substrate is in the closed conformation. Right
panel, threonine 423 phosphorylation (and possibly other
phosphorylation events regulating the ID) only occur if the Pak
substrate molecule is in an open conformation. Threonine 423 accessibility is depicted as a change in shading in this model, which
should reflect a conformational change of the kinase domain in the open
conformation. As an alternative, the closed conformation could also
lead to masking of threonine 423.
Pak and human Pak1 is identical up to amino acid 178, where human Pak1 contains an additional aspartic acid residue). Using mutagenesis, they identified additional amino acids (conserved in
hPak1) essential for the inhibitory function. These amino acids are
located within the COOH-terminal portion of the PBD/ID region (glutamic
acid 116/glutamine 117 and aspartic acid 126). As we demonstrated for
leucine 107, these mutations do not disrupt GTPase binding but abolish
the inhibitory function, supporting the idea that both functions have
different determinants within this region. A more indirect approach
using the yeast two-hybrid system was used to demonstrate that the
equivalent regulatory and kinase domains of the yeast S. pombe Pak1 interact in a Cdc42-sensitive fashion (10).
![]()
ACKNOWLEDGEMENTS
II antiserum and
Melanie H. Cobb for providing the pGEX-KG/rpak1 construct. We thank
Toni Lestelle for expert secretarial assistance.
![]()
FOOTNOTES
Supported by an EMBO postdoctoral fellowship.
![]()
ABBREVIATIONS
S, guanosine 5'-3-O-(thio)triphosphate;
PKC, protein kinase C;
PCR, polymerase chain reaction;
aa, amino acid(s).
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Taylor, S. S.,
and Radzio-Andzelm, E.
(1997)
Curr. Opin. Chem. Biol.
1,
219-226[CrossRef][Medline]
[Order article via Infotrieve]
2.
Kemp, B. E.,
and Pearson, R. B.
(1991)
Biochim. Biophys. Acta
1094,
67-76[Medline]
[Order article via Infotrieve]
3.
Sells, M. A.,
and Chernoff, J.
(1997)
Trends Cell Biol.
7,
162-167
4.
Benner, G. E.,
Dennis, P. B.,
and Masaracchia, R. A.
(1995)
J. Biol. Chem.
270,
21121-21128 5.
Yu, J. S.,
Chen, W. J.,
Ni, M. H.,
Chan, W. H.,
and Yang, S. D.
(1998)
Biochem. J.
334,
121-131
6.
Lee, N.,
MacDonald, H.,
Reinhard, C.,
Halenbeck, R.,
Roulston, A.,
Shi, T.,
and Williams, L. T.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
13642-13647 7.
Rudel, T.,
and Bokoch, G. M.
(1997)
Science
276,
1571-1574 8.
Walter, B. N.,
Huang, Z.,
Jakobi, R.,
Tuazon, P. T.,
Alnemri, E. S.,
Litwack, G.,
and Traugh, J. A.
(1998)
J. Biol. Chem.
273,
28733-28739 9.
Zhao, Z. S.,
Manser, E.,
Chen, Z. Q.,
Chong, C.,
Leung, T.,
and Lim, L.
(1998)
Mol. Cell. Biol.
18,
2153-2163 10.
Tu, H.,
and Wigler, M.
(1999)
Mol. Cell. Biol.
19,
602-611 11.
Bokoch, G. M.,
Reilly, A. M.,
Daniels, R. H.,
King, C. C.,
Olivera, A.,
Spiegel, S.,
and Knaus, U. G.
(1998)
J. Biol. Chem.
273,
8137-8144 12.
Lian, J. P.,
Huang, R.,
Robinson, D.,
and Badwey, J. A.
(1998)
J. Immunol.
161,
4375-4381 13.
Sells, M. A.,
Knaus, U. G.,
Bagrodia, S.,
Ambrose, D. M.,
Bokoch, G. M.,
and Chernoff, J.
(1997)
Curr. Biol.
7,
202-210
14.
Burbelo, P. D.,
Dreschsel, D.,
and Hall, A.
(1995)
J. Biol. Chem.
270,
29071-29074 15.
Daniels, R. H.,
Zenke, F. T.,
and Bokoch, G. M.
(1999)
J. Biol. Chem.
274,
6047-6050 16.
Brown, J. L.,
Stowers, L.,
Baer, M.,
Trejo, J.,
Coughlin, S.,
and Chant, J.
(1996)
Curr. Biol.
6,
598-605[CrossRef][Medline]
[Order article via Infotrieve]
17.
Martin, G. A.,
Bollag, G.,
McCormick, F.,
and Abo, A.
(1995)
EMBO J.
14,
1970-1978[Medline]
[Order article via Infotrieve]
18.
Manser, E.,
Huang, H. Y.,
Loo, T. H.,
Chen, X. Q.,
Dong, J. M.,
Leung, T.,
and Lim, L.
(1997)
Mol. Cell. Biol.
17,
1129-1143[Abstract]
19.
Steinberg, R. A.,
Cauthron, R. D.,
Symcox, M. M.,
and Shuntoh, H.
(1993)
Mol. Cell. Biol.
13,
2332-2341 20.
Knaus, U. G.,
Wang, Y.,
Reilly, A. M.,
Warnock, D.,
and Jackson, J. H.
(1998)
J. Biol. Chem.
273,
21512-21518 21.
Abo, A.,
Qu, J.,
Cammarano, M. S.,
Dan, C.,
Fritsch, A.,
Baud, V.,
Belisle, B.,
and Minden, A.
(1998)
EMBO J.
17,
6527-6540[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S. Nola, M. Sebbagh, S. Marchetto, N. Osmani, C. Nourry, S. Audebert, C. Navarro, R. Rachel, M. Montcouquiol, N. Sans, et al. Scrib regulates PAK activity during the cell migration process Hum. Mol. Genet., November 15, 2008; 17(22): 3552 - 3565. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Smith, Z. M. Jaffer, J. Chernoff, and A. J. Ridley PAK1-mediated activation of ERK1/2 regulates lamellipodial dynamics J. Cell Sci., November 15, 2008; 121(22): 3729 - 3736. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ambrogio, C. Voena, A. D. Manazza, C. Martinengo, C. Costa, T. Kirchhausen, E. Hirsch, G. Inghirami, and R. Chiarle The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation Cancer Res., November 1, 2008; 68(21): 8899 - 8907. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Maceyka, S. E. Alvarez, S. Milstien, and S. Spiegel Filamin A Links Sphingosine Kinase 1 and Sphingosine-1-Phosphate Receptor 1 at Lamellipodia To Orchestrate Cell Migration Mol. Cell. Biol., September 15, 2008; 28(18): 5687 - 5697. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Li, Y. H. El-Hayek, B. Liu, Y. Chen, E. Gomez, X. Wu, K. Ning, L. Li, N. Chang, L. Zhang, et al. Direct-Current Electrical Field Guides Neuronal Stem/Progenitor Cell Migration Stem Cells, August 1, 2008; 26(8): 2193 - 2200. [Abstract] [Full Text] [PDF] |
||||
|
|